

**Certification of Substances Department**

**Certificate of suitability**  
**No. R1-CEP 2007-235-Rev 02**

1 *Name of the substance:*

2 **ERYTHROMYCIN ETHYLSUCCINATE**

3 *Name of holder:*

4 **ANUH PHARMA LTD**

5 3-A, Shivsagar Estate, North Wing

6 Dr Annie Besant Road, Worli

7 India-400 018 Mumbai, Maharashtra

8 *Site(s) of production:*

9 **SEE ANNEX 1**

10

**THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**

11

**R1-CEP 2007-235-REV 01**

12 After examination of the information provided on the manufacturing method and subsequent  
13 processes (including purification) for this substance on the site(s) of production listed in annex, we  
14 certify that the quality of the substance is suitably controlled by the current version of the  
15 monograph **ERYTHROMYCIN ETHYLSUCCINATE** no. 274 of the European Pharmacopoeia,  
16 current edition including supplements, only if it is supplemented by the test(s) mentioned below,  
17 based on the analytical procedure(s) given in annex.

18 Any unspecified impurity detected by the test for related substances of the monograph is  
19 limited to not more than 0.2%.

20 – Test for residual solvents by gas chromatography (Annex 2)  
21 Acetone not more than 5000 ppm

22 In the last steps of the synthesis water is used as solvent.

23 The substance is packed in a double polyethylene bag placed in a polyethylene drum.

24 The holder of the certificate has declared the absence of use of material of human or animal  
25 origin in the manufacture of the substance.

26 The submitted dossier must be updated after any significant change that may alter the quality,  
27 safety or efficacy of the substance.

28 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice  
29 and in accordance with the dossier submitted.


Address: 7 Allée Kastner, CS 30026

F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu

Internet: <http://www.edqm.eu>

- 30 Failure to comply with these provisions will render this certificate void.
- 31 This certificate is renewed from **30 June 2015** according to the provisions of Resolution AP-CSP  
32 (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment,  
33 and the related guidelines.
- 34 This certificate has two annexes, the first of 1 page and the second of 2 pages.
- 35 This certificate has:  
36 lines.

  
On behalf of the  
Director of EDQM



Strasbourg, 6 December 2017

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

**Anuh Pharma Ltd**, as holder of the certificate of suitability

**R1-CEP 2007-235-Rev 02 for Erythromycin ethylsuccinate**

hereby authorises .....  
*(name of the pharmaceutical company)*

to use the above-mentioned certificate of suitability in support of their application(s) for the following  
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

The holder also certifies that no significant changes to the operations as described in the CEP dossier  
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*: